JPMorgan Ultra Short Income ETF vs Novartis AG — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.45, while Novartis AG trades at $152.4 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while JPMorgan Ultra Short Income ETF pays none, and Novartis AG is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| JPST | NVS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.78 | $168.62 |
52-Week Low | $50.40 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Trailing returns across standard periods
Latest headlines on both assets
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →